9.2 PROTOCOL SPECIFIC RESEARCH SUPPORT The goal of Protocol-Specific Research is to provide research nursing and data management support for conducting and completing innovative, early feasibility or proof-of-principle clinical trials originating from Arizona Cancer Center Programs. Priorities to obtain funding through this core will be given to translational clinical research studies. These may emanate from basic research at the Arizona Cancer Center, or they may involve laboratory correlates with concepts developed by clinicians. In either case, the top priority will be given to Investigator Initiated Trials (IITs). The University of Arizona continues to support the growth of the Investigator Initiated and early Phase I research studies, as demonstrated by an additional allocation of $500,000 in the current year for our clinical research efforts overall, and very specifically the innovative and early phase clinical studies. Minimum criteria for access to AZCC Protocol-Specific Research funds include the following: ? Research hypothesis was generated by an AZCC clinical investigator; ? Clinical trial represents a new initiative; ? Clinical trial has received approval with high priority from the AZCC Scientific Review Committee and the University of Arizona Human Subject's Committee; ? Principal investigator is a member of the AZCC; ? Final approval and disposition of these funds will be made by the AZCC Resource Committee. The Arizona Cancer Center Resource Allocation Committee meets bi-monthly and is composed of clinical investigators in leadership positions in AZCC Programs and Administration.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA023074-34
Application #
8377813
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
34
Fiscal Year
2012
Total Cost
$87,544
Indirect Cost
$29,759
Name
University of Arizona
Department
Type
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Knudsen, Erik S; Balaji, Uthra; Mannakee, Brian et al. (2018) Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility. Gut 67:508-520
Boese, Cody J; Nye, Jonathan; Buster, Daniel W et al. (2018) Asterless is a Polo-like kinase 4 substrate that both activates and inhibits kinase activity depending on its phosphorylation state. Mol Biol Cell 29:2874-2886
Sohail, Atif; Mushtaq, Adeela; Iftikhar, Ahmad et al. (2018) Emerging immune targets for the treatment of multiple myeloma. Immunotherapy 10:265-282
Doane, Cynthia J; Patil, Karuna; Hoffman, Emely A et al. (2018) Supernumerary Incisors in CB6F1 Mice Conditioned with Chemotherapy and Total Body Irradiation before Bone Marrow Transplantation. Comp Med 68:349-352
Bea, J W; Hsu, C-H; Blew, R M et al. (2018) Use of iDXA spine scans to evaluate total and visceral abdominal fat. Am J Hum Biol 30:
Lent, Adrienne B; O'Connor, Patrick A; Reikowsky, Ryan C et al. (2018) Quit outcomes among clients ineligible for cessation medication through the state quitline: a retrospective, observational study. BMC Public Health 18:1001
Bulkley, Joanna E; McMullen, Carmit K; Grant, Marcia et al. (2018) Ongoing ostomy self-care challenges of long-term rectal cancer survivors. Support Care Cancer 26:3933-3939
Zaim, Samir Rachid; Li, Qike; Schissler, A Grant et al. (2018) Emergence of pathway-level composite biomarkers from converging gene set signals of heterogeneous transcriptomic responses. Pac Symp Biocomput 23:484-495
Kobes, Joseph E; Georgiev, George I; Louis, Anthony V et al. (2018) A Comparison of Iron Oxide Particles and Silica Particles for Tracking Organ Recellularization. Mol Imaging 17:1536012118787322
Kelly, K R; Espitia, C M; Zhao, W et al. (2018) Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia 32:230-233

Showing the most recent 10 out of 1336 publications